Author:
Bezeha O.V.,Yemchenko Y.O.,Vasylyeva K.V.
Abstract
Psoriasis is a chronic immune-mediated genetic disease with systemic and cutaneous manifestations that can significantly impair patients' quality of life. 2-3% of the world population suffers from psoriasis, and this imposes a significant economic burden on patients. Aetiology is mainly related to genes and environmental factors. The pathophysiology of psoriasis is characterized by T cells and dendritic cells, antimicrobial peptides, genetic predisposition, lipoprotein-2, galactosin-3, fractalkine, vaspin, human neutrophil peptides, etc. in the progression of psoriasis. For patients with psoriasis, conventional treatments include corticosteroids, vitamin D3 analogs, calcineurin inhibitors, methotrexate, cyclosporine, acitretin, phototherapy, and biological agents, etc. Today, there are various standard topical therapeutic approaches that can help control the condition for months to years, however, complete recovery from psoriasis with these treatments has not been reported. Therefore, researchers around the world are mainly considering the possibility of using various nanotechnological therapies for complete recovery. New drug delivery carriers, in particular nanocarriers, can overcome certain disadvantages of conventional treatment methods, such as: dose minimization, frequency of administration, and dose-dependent side effects. Nanodermatology is a new multidisciplinary science that is gaining more and more recognition in the treatment of psoriasis. The use of nanotechnology makes it possible to select drugs to achieve dermal targeting, increase efficiency and minimize unwanted effects. Currently, these nanocarriers are becoming increasingly popular as delivery vehicles for psoriasis drugs due to their non-toxicity, natural degradability, excellent biocompatibility and biodegradability, they do not cause harmful inflammatory reactions and are easily excreted from the body. Reports of nanocarrier delivery for the treatment of psoriasis have shown improved efficacy and reduced toxicity compared to standard pharmacotherapy. To better clarify the application of nanotechnology in the treatment of psoriasis, various drugs based on nanocarriers will be summarized. This review provides a concise overview of the pathophysiology, epidemiology, clinical diagnosis, and classical pharmacotherapy of psoriasis. The review also summarizes various nanotechnological treatments for the effective treatment of psoriasis.
Publisher
Ukrainian Medical Stomatological Academy
Subject
General Materials Science
Reference25 articles.
1. Ali F, Neha K, Sharma K, et al. Nanotechnology-based Medicinal Products and Patents: A Promising Way to Treat Psoriasis. Curr Drug Deliv. 2022;19(5):587-599.
2. Bahadur S, Sharma M. Liposome based drug delivery for the management of psoriasis - A comprehensive review. Curr Pharm Biotechnol. 2023;24(11):1383-1396.
3. Bezeha OV, Popova IB. Vplyv antyoksydantnoi terapii na tiazhkist perebihu, efektyvnist likuvannia ta tryvalist remisii u khvorykh na psoriaz [The influence of antioxidant therapy on the severity of the course, the effectiveness of the treatment and the duration of remission in psoriasis patients]. Aktualni problemy suchasnoi medytsyny: Visnyk ukrainskoi medychnoi stomatolohichnoi akademii. 2019; 2 (66): 136-141. (Ukrainian).
4. Bezeha OV, Popova IB, Vasylyeva KV. Dosvid zastosuvannia Resveratrolu v kompleksnomu likuvanni khvorykh na psoriaz [Experience in the use of Resveratrol in the complex treatment of patients with psoriasis]. Dermatovenerolohyia. Kosmetolohyia. Seksopatolohyia, 2019;3(1):58-64.
5. Gomes GS, Frank LA, Contri RV, et al. Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis. Int J Pharm. 2023 Jan 25;631:122535.